US FDA warns Teva over propofol manufacturing violations
This article was originally published in Scrip
Executive Summary
The US FDA has cited Teva Pharmaceutical Industries for significant good manufacturing practice violations that contributed to a shortage of the sedative-hypnotic drug propofol.